We collect cookies to analyze our website traffic and performance; we never collect any personal data. Cookie Policy
Accept
NEW YORK DAWN™NEW YORK DAWN™NEW YORK DAWN™
Notification Show More
Font ResizerAa
  • Home
  • Trending
  • New York
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
  • Crypto & NFTs
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Art
  • Health
  • Sports
  • Entertainment
Reading: Lowered-dose anticoagulants not noninferior for recurrent venous thromboembolism
Share
Font ResizerAa
NEW YORK DAWN™NEW YORK DAWN™
Search
  • Home
  • Trending
  • New York
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
  • Crypto & NFTs
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Art
  • Health
  • Sports
  • Entertainment
Follow US
NEW YORK DAWN™ > Blog > Health > Lowered-dose anticoagulants not noninferior for recurrent venous thromboembolism
Lowered-dose anticoagulants not noninferior for recurrent venous thromboembolism
Health

Lowered-dose anticoagulants not noninferior for recurrent venous thromboembolism

Last updated: December 7, 2024 11:32 pm
Editorial Board Published December 7, 2024
Share
SHARE

Noninferiority of reduced- versus full-dose anticoagulants can’t be confirmed in sufferers with venous thromboembolism who want prolonged anticoagulation, based on a examine to be introduced on the annual assembly of the American Society of Hematology, held from Dec. 7 to 10 in San Diego.

Francis Couturaud, M.D., Ph.D., from the College of Brest in France, and colleagues carried out a multicenter, potential, randomized trial evaluating prolonged anticoagulation with reduced-dose versus full-dose direct oral anticoagulants in sufferers with venous thromboembolism at excessive danger for recurrence, who have been initially handled for six to 24 months.

The researchers discovered that recurrent venous thromboembolism occurred in 19 of 1,383 sufferers within the reduced-dose group versus 15 of 1,385 within the full-dose group throughout the 36-month median follow-up (five-year cumulative incidence, 2.2 versus 1.8%; hazard ratio, 1.32; 95% confidence interval, 0.67 to 2.60; P = 0.23 for noninferiority). Clinically related bleeding occurred in 96 sufferers within the reduced-dose group and 154 within the full-dose group (five-year cumulative incidence, 9.9 versus 15.2%).

The composite final result of recurrent venous thromboembolism and clinically related bleeding occurred in 113 and 166 sufferers within the reduced- and full-dose teams, respectively (five-year cumulative incidence, 11.8 versus 16.5%). All-cause loss of life occurred in 4.3 and 6.1% of sufferers within the reduced- and full-dose teams, respectively.

“The noninferiority of a reduced-dose versus a full-dose of direct anticoagulants to prevent recurrent venous thromboembolism could not be proven,” the authors write.

A number of authors disclosed ties to the pharmaceutical business.

Extra info:
AbstractMore Info

© 2024 HealthDay. All rights reserved.

Quotation:
Lowered-dose anticoagulants not noninferior for recurrent venous thromboembolism (2024, December 6)
retrieved 7 December 2024
from https://medicalxpress.com/information/2024-12-dose-anticoagulants-noninferior-recurrent-venous.html

This doc is topic to copyright. Aside from any honest dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for info functions solely.

You Might Also Like

Rugby headgear cannot forestall concussion—however new supplies may soften the blows over a profession

Temporal and noise-resilient strategies for refined cardiovascular diagnostic imaging

Uncovering behavioral clues to childhood maltreatment

Ritz peanut butter crackers recalled over labeling mistake

US cuts to HIV help might result in 4 million deaths, UN warns

TAGGED:anticoagulantsnoninferiorrecurrentReduceddosethromboembolismvenous
Share This Article
Facebook Twitter Email Print

Follow US

Find US on Social Medias
FacebookLike
TwitterFollow
YoutubeSubscribe
TelegramFollow
Popular News
A ‘Malicious program’ method might allow growth of latest antimalarial medicine
Health

A ‘Malicious program’ method might allow growth of latest antimalarial medicine

Editorial Board March 5, 2025
12 Easy Methods to Refresh Your Kitchen for Spring
Right this moment in Historical past: November 23, former KGB spy and Putin critic dies in London
Customized bone and tissue regeneration gel exhibits effectiveness in rats
A Streamlined Spring Risotto With Chard and Pancetta

You Might Also Like

FDA absolutely approves Moderna’s COVID vaccine for some younger youngsters
Health

FDA absolutely approves Moderna’s COVID vaccine for some younger youngsters

July 12, 2025
Results of poor sleep might contribute to alcohol issues in school college students
Health

Results of poor sleep might contribute to alcohol issues in school college students

July 12, 2025
Weight problems linked to what’s on native restaurant menus
Health

Weight problems linked to what’s on native restaurant menus

July 12, 2025
Extra misfolded proteins than beforehand identified might contribute to Alzheimer’s and dementia
Health

Extra misfolded proteins than beforehand identified might contribute to Alzheimer’s and dementia

July 11, 2025

Categories

  • Health
  • Sports
  • Politics
  • Entertainment
  • Technology
  • World
  • Art

About US

New York Dawn is a proud and integral publication of the Enspirers News Group, embodying the values of journalistic integrity and excellence.
Company
  • About Us
  • Newsroom Policies & Standards
  • Diversity & Inclusion
  • Careers
  • Media & Community Relations
  • Accessibility Statement
Contact Us
  • Contact Us
  • Contact Customer Care
  • Advertise
  • Licensing & Syndication
  • Request a Correction
  • Contact the Newsroom
  • Send a News Tip
  • Report a Vulnerability
Term of Use
  • Digital Products Terms of Sale
  • Terms of Service
  • Privacy Policy
  • Cookie Settings
  • Submissions & Discussion Policy
  • RSS Terms of Service
  • Ad Choices
© 2024 New York Dawn. All Rights Reserved.
Welcome Back!

Sign in to your account

Lost your password?